Loading…
Chinese biotechnology company; specific product/therapeutic focus not independently confirmed.
Chinese biotechnology company; specific product/therapeutic focus not independently confirmed.
Moat: none
Headquarters: China · Employees: 546
Size HOB Biotech (688656.SS) is a China Health Care company (Medical Specialties) with a market value of $972M, the 2345th largest of 4,839 China companies the cockpit tracks. Shares closed at CN¥102.00 on 6 Nov 2026.
Performance Over six months the shares fell 21.7%, against -18.7% for the median peer and -16.4% for the China market (cap-weighted) — 5th lowest of 21 in its peer set.
Growth Revenue grew 6.4% over the last twelve months (peer median +6.3%); the operating margin is 7.2% (peer median 10.9%).
Valuation It trades at 188.9× forward earnings against a peer median of 23.6× (2nd most expensive of 16).
Price implies For today's price to make sense, revenue must grow about 40% a year for seven years (Req g). Recent delivered growth is +12%, so the hurdle is +28 pp: the price needs faster growth than the company has been delivering — of companies that just grew 25–50% a year, 93.8% slowed down over the next four years.
Capital Return on invested capital runs 0.9 points below its cost of capital (8.6% WACC).
Next results Next results expected around 29 Apr 2027 (exchange calendar; dates can move).
| TTM | FY2025 | FY2024 | FY2023 | FY2022 | |
|---|---|---|---|---|---|
| Revenue | CN¥412M | CN¥395M | CN¥398M | CN¥390M | CN¥317M |
| Revenue growth | — | -1% | +2% | +23% | — |
| Gross profit | CN¥277M | CN¥201M | CN¥235M | CN¥227M | CN¥187M |
| EBITDA | n/a | CN¥87.4M | CN¥98.2M | CN¥101M | CN¥79.8M |
| Net income | CN¥26.2M | CN¥23.2M | CN¥36.8M | CN¥47.3M | CN¥41.7M |
| Free cash flow | CN¥66.8M | -CN¥961,330 | -CN¥53.3M | -CN¥75.3M | -CN¥162M |
| Capital expenditure | CN¥26.7M | CN¥73.9M | CN¥155M | CN¥178M | CN¥220M |
| Total debt | CN¥11.5M | CN¥47.4M | CN¥118M | CN¥55.8M | CN¥65.4M |
The default views of Competitor Analysis ▸ Charts, drawn from the same data. Open them in the cockpit to change the axes, pin companies and read every value.
Peer set: Industry: the same industry and sector in any market, nearest in size. This is the same default set the interactive Competitor Analysis opens with.
| Measure | 688656.SS | Peer median | Rank in peer set |
|---|---|---|---|
| 1-month return | -19.4% | -2.6% | 3rd lowest of 21 |
| 6-month return | -21.7% | -18.7% | 5th lowest of 21 |
| Distance from 52-week high | -53.0% | -34.7% | 5th lowest of 21 |
| Revenue growth (TTM) | +6.4% | +6.3% | 11th highest of 21 |
| Operating margin | 7.2% | 10.9% | 9th lowest of 21 |
| Forward P/E | 188.9× | 23.6× | 2nd most expensive of 16 |
| Growth the price implies (Req g, 7 yrs) | 40.1% | 7.7% | 2nd most demanding of 14 |
| Growth delivered (Del g) | +12.4% | +12.1% | 6th highest of 14 |
| Hurdle (Req g minus delivered) | +27.7 pp | +1.6 pp | 2nd most demanding of 14 |
| ROIC minus cost of capital | -0.9 pp | +1.1 pp | 10th lowest of 20 |
| Company | Market | Market cap | 6M return | Revenue growth | Op. margin | Forward P/E | Req g | Delivered g |
|---|---|---|---|---|---|---|---|---|
| HOB Biotech 688656.SS | China | $972M | -22% | +6% | 7% | 188.9× | 40.1% | +12.4% |
| Xiangyu Medical 688626.SS | China | $969M | -31% | 0% | 4% | 62.1× | n/a | n/a |
| Eckert & Ziegler EUZ.DE | Germany | $969M | -7% | +4% | 25% | 17.0× | 7.2% | +12.1% |
| Beijing Hotgen Biotech 688068.SS | China | $966M | -38% | +8% | -94% | n/a | n/a | n/a |
| Artivion AORT | United States | $985M | -20% | +16% | 7% | 3,912.9× | n/a | n/a |
| Kuros Biosciences KURN.SW | Switzerland | $953M | +3% | +41% | 6% | 73.8× | n/a | n/a |
| Castle Biosciences CSTL | United States | $993M | +64% | +3% | -9% | n/a | n/a | n/a |
| Shenzhen YHLO Biotech 688575.SS | China | $950M | -20% | +3% | 12% | 37.2× | 3.1% | +12.7% |
| Shantou Institute of Ultrasonic Instruments 301602.SZ | China | $944M | -19% | +4% | 30% | n/a | 13.1% | +4.6% |
| Caina Technology 301122.SZ | China | $938M | +60% | +61% | 0% | 72.0× | n/a | n/a |
| Aidite (Qinhuangdao) Technology 301580.SZ | China | $919M | -20% | +17% | 18% | 27.1× | 19.9% | +23.3% |
| Seegene 096530.KS | South Korea | $915M | +26% | +12% | 13% | 15.9× | -3.4% | -15.9% |
| Ningbo Jansen Superconducting Technologies 688805.SS | China | $915M | -30% | +36% | 14% | n/a | 47.2% | +17.1% |
| LifeTech Scientific 1302.HK | Hong Kong | $914M | -18% | +1% | 12% | 23.5× | 13.3% | +15.5% |
| Ceribell CBLL | United States | $1.03B | +32% | +31% | -70% | n/a | n/a | n/a |
| Beijing SDL Technology 002658.SZ | China | $910M | -21% | -13% | 9% | 23.6× | 18.0% | +2.9% |
| Shanghai Runda Medical Technology 603108.SS | China | $909M | -25% | -12% | -2% | 25.1× | 22.2% | -0.2% |
| Mani 7730.T | Japan | $909M | -15% | +10% | 30% | 18.4× | 1.5% | +13.9% |
| Integra LifeSciences IART | United States | $1.04B | -4% | +1% | 12% | 5.8× | 5.2% | +3.6% |
| Edan Instruments 300206.SZ | China | $1.05B | -19% | +14% | 17% | 18.8× | 7.7% | -2.9% |
| Bioventus BVS | United States | $894M | +1% | +4% | 10% | 13.1× | 6.9% | +12.1% |